158 related articles for article (PubMed ID: 36226867)
1. Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey.
George DJ; Mohamed AF; Tsai JH; Karimi M; Ning N; Jayade S; Botteman M
Cancer Med; 2023 Mar; 12(5):6040-6055. PubMed ID: 36226867
[TBL] [Abstract][Full Text] [Related]
2. Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation.
Rentz AM; Mansukhani SG; Liu J; Lloyd AJ; Heidenreich S; Matza LS; Dawson NA; Shore N; Freedland SJ
Urol Oncol; 2021 Jun; 39(6):367.e7-367.e17. PubMed ID: 33736976
[TBL] [Abstract][Full Text] [Related]
3. Patients' Preferences for the Treatment of Metastatic Castrate-resistant Prostate Cancer: A Discrete Choice Experiment.
Eliasson L; de Freitas HM; Dearden L; Calimlim B; Lloyd AJ
Clin Ther; 2017 Apr; 39(4):723-737. PubMed ID: 28366592
[TBL] [Abstract][Full Text] [Related]
4. Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment.
Srinivas S; Mohamed AF; Appukkuttan S; Botteman M; Ng X; Joshi N; Tsai JH; Fang J; Waldeck AR; Simmons SJ
Cancer Med; 2020 Sep; 9(18):6586-6596. PubMed ID: 32725755
[TBL] [Abstract][Full Text] [Related]
5. Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment.
Uemura H; Matsubara N; Kimura G; Yamaguchi A; Ledesma DA; DiBonaventura M; Mohamed AF; Basurto E; McKinnon I; Wang E; Concialdi K; Narimatsu A; Aitoku Y
BMC Urol; 2016 Nov; 16(1):63. PubMed ID: 27814714
[TBL] [Abstract][Full Text] [Related]
6. Physician preferences for non-metastatic castration-resistant prostate cancer treatment.
Srinivas S; Mohamed AF; Appukkuttan S; Botteman M; Ng X; Joshi N; Horodniceanu E; Waldeck AR; Simmons SJ
BMC Urol; 2020 Jun; 20(1):73. PubMed ID: 32571276
[TBL] [Abstract][Full Text] [Related]
7. Understanding Treatment Strategies and Preferences in Nonmetastatic Castration-Resistant Prostate Cancer From the Japanese Physician Perspective.
Suzuki K; Grillo V; Chen Y; Singh S; Ledesma DA
JCO Glob Oncol; 2021 Feb; 7():302-310. PubMed ID: 33617305
[TBL] [Abstract][Full Text] [Related]
8. Patient Preferences for Metastatic Hormone-Sensitive Prostate Cancer Treatments: A Discrete Choice Experiment Among Men in Three European Countries.
de Freitas HM; Ito T; Hadi M; Al-Jassar G; Henry-Szatkowski M; Nafees B; Lloyd AJ
Adv Ther; 2019 Feb; 36(2):318-332. PubMed ID: 30617763
[TBL] [Abstract][Full Text] [Related]
9. A qualitative research study in Japan investigating patients' experience with metastatic castration-resistant prostate cancer: from diagnosis to decision for Ra-223 treatment.
Akakura K; Uemura H; Miyazaki K; Stroupe A; Seo C; Uzumcu A; Ledesma DA
Future Oncol; 2021 Dec; 17(36):5103-5118. PubMed ID: 34664992
[TBL] [Abstract][Full Text] [Related]
10. Unmet needs in non-metastatic castration-resistant prostate cancer from the Japanese patient perspective: a discrete choice experiment.
Uemura H; Matsushima H; Yokomizo A; Kobayashi K; Arai G; Satoh T; Grillo V; Chen Y; Singh S; Ledesma DA
BMJ Open; 2021 Aug; 11(8):e052471. PubMed ID: 34400460
[TBL] [Abstract][Full Text] [Related]
11. Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.
Baciarello G; Delva R; Gravis G; Tazi Y; Beuzeboc P; Gross-Goupil M; Bompas E; Joly F; Greilsamer C; Hon TNT; Barthelemy P; Culine S; Berdah JF; Deblock M; Ratta R; Flechon A; Cheneau C; Maillard A; Martineau G; Borget I; Fizazi K;
Eur Urol; 2022 Mar; 81(3):234-240. PubMed ID: 34789394
[TBL] [Abstract][Full Text] [Related]
12. Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer.
Klaassen Z; Howard LE; de Hoedt A; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
Cancer; 2017 May; 123(9):1528-1535. PubMed ID: 28026865
[TBL] [Abstract][Full Text] [Related]
13. Patient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes.
Zeidan AM; Tsai JH; Karimi M; Schmier J; Jayade S; Zormpas E; Hassan A; Ruiters D; Anthony C; Hill K; Wert T; Botteman M
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):e853-e866. PubMed ID: 35729009
[TBL] [Abstract][Full Text] [Related]
14. Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry.
Verry C; Vincendeau S; Massetti M; Blachier M; Vimont A; Bazil ML; Bernardini P; Pettré S; Timsit MO
Target Oncol; 2022 Jul; 17(4):441-451. PubMed ID: 35841526
[TBL] [Abstract][Full Text] [Related]
15. A Study of Patient Preferences for the Treatment of Non-small Cell Lung Cancer in Western China: A Discrete-Choice Experiment.
Liu F; Hu H; Wang J; Chen Y; Hui S; Hu M
Front Public Health; 2021; 9():653450. PubMed ID: 33842426
[No Abstract] [Full Text] [Related]
16. Patients' Preferences for Systemic Lupus Erythematosus Treatments-A Discrete Choice Experiment.
Collacott H; Phillips-Beyer A; Krucien N; Flamion B; Marsh K
Patient; 2024 May; 17(3):287-300. PubMed ID: 38270788
[TBL] [Abstract][Full Text] [Related]
17. Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.
Francini E; Montagnani F; Nuzzo PV; Gonzalez-Velez M; Alimohamed NS; Rosellini P; Moreno-Candilejo I; Cigliola A; Rubio-Perez J; Crivelli F; Shaw GK; Zhang L; Petrioli R; Bengala C; Francini G; Garcia-Foncillas J; Sweeney CJ; Higano CS; Bryce AH; Harshman LC; Lee-Ying R; Heng DYC
JAMA Netw Open; 2021 Jul; 4(7):e2116536. PubMed ID: 34292336
[TBL] [Abstract][Full Text] [Related]
18. Trade-offs between overall survival and side effects in the treatment of metastatic breast cancer: eliciting preferences of patients with primary and metastatic breast cancer using a discrete choice experiment.
Bullen A; Ryan M; Ennis H; Gray E; Loría-Rebolledo LE; McIntyre M; Hall P
BMJ Open; 2024 Apr; 14(4):e076798. PubMed ID: 38684245
[TBL] [Abstract][Full Text] [Related]
19. Patient preferences for treatments to delay bone metastases.
Hauber AB; Arellano J; Qian Y; González JM; Posner JD; Mohamed AF; Gatta F; Tombal B; Body JJ
Prostate; 2014 Nov; 74(15):1488-97. PubMed ID: 25132622
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review of Patients' Values, Preferences, and Expectations for the Treatment of Metastatic Prostate Cancer.
Connor MJ; Genie MG; Burns D; Bass EJ; Gonzalez M; Sarwar N; Falconer A; Mangar S; Dudderidge T; Khoo V; Winkler M; Ahmed HU; Watson V
Eur Urol Open Sci; 2022 Feb; 36():9-18. PubMed ID: 34977691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
